Crucell Signs Second Exclusive License Agreement with Talecris Biotherapeutics
Crucell N.V. announced that it has signed a second exclusive, commercial license agreement with Talecris Biotherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line.
Crucell will receive an upfront payment of $1.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $20 million. Further financial details of the agreement were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies

Coupled Proteins - How human cells react to external signals and further process them

'Trojan horse' anticancer drug disguises itself as fat - Promising system delivers chemo drug straight into tumors with fewer side effects
Oncothyreon announces issuance of patent for PX-867
Hypocapnia
UCB strengthens strategic alliance with WILEX - UCB's position as a strategic investor now represents 18% of WILEX shares
Cardio3 BioSciences Establishes US Subsidiary in Rochester, MN
